Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8479-8485

  Marsman, Willem A ^a   Birjmohun, Rakesh S ^a   Van Rees, Bastiaan P ^a   Caspers, Eric ^a   Offerhaus, G Johan A ^a   Bosma, Piter J ^a   Van Lanschot, J Jan B ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER STAGING; CARCINOGENESIS; CARDIA CARCINOMA; DISSEMINATED CANCER; ESOPHAGUS CARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; TCF1 GENE; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; CARDIA; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; STOMACH NEOPLASMS;

EID: 11144242804     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0839     Document Type: Article

References (45)

1. Devesa SS, Blot WJ, Fraumeni JF, Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (Phila) 1998;83:2049-53.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc 1991;265:1287-9.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
4. MacDonald WC, MacDonald JB. Adenocarcinoma of the esophagus and/or gastric cardia. Cancer (Phila) 1987;60:1094-8.
5. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (Bethesda) 1998;90:150-5.
6. Kalish RJ, Clancy PE, Orringer MB, Appelman HD. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology 1984;86:461-7.
7. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000;231:303-21.
8. Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 1999;86:529-35.
9. Steup WH, De Leyn P, Deneffe G, et al. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Tnorac Cardiovasc Surg 1996;111:85-94; discussion 94-5.
10. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
11. Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000;46:9-13.
12. van Sandick JW, van Lanschot JB, van Felius L, et al. Intestinal metaplasia of the esophagus or esophagogastric junction: evidence of distinct clinical, pathologic, and histochemical staining features. Am J Clin Pathol 2002;117:117-25.
13. Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology 2000;119:683-90.
14. Buskens CJ, Sivula A, van Rees BP, et al. Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut 2003;52:1678-83.
15. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-7.
16. Barrett MT, Galipeau PC, Sanchez CA, Emond MJ, Reid BJ. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996;12:1873-8.
17. Hammoud Z, Kaleem Z, Cooper J, et al. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996;56:4499-502.
18. Dolan K, Garde J, Gosney J, et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998;78:950-7.
19. Gleeson CM, Sloan JM, McGuigan JA, et al. Allelotype analysis of adenocarcinoma of the gastric cardia. Br J Cancer 1997;76:1455-65.
20. Yanagi M, Keller G, Mueller J, et al. Comparison of loss of heterozygosity and microsatellite instability in adenocarcinomas of the distal esophagus and proximal stomach. Virchows Arch 2000;437:605-10.
21. Roose J, Huls G, van Beest M, et al. Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science (Wash DC) 1999;285:1923-6.
22. Entius MM, Keller JJ, Westerman AM, et al. Molecular genetic alterations in hamartomatous polyps and carcinomas of patients with Peutz-Jeghers syndrome. J Clin Pathol 2001;54:126-31.
23. van Dekken H, Geelen E, Dinjens WN, et al. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999;59:748-52.
24. van Rees BP, Caspers E, zur Hausen A, et al. Different pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway. Am J Pathol 2002;161:1207-13.
25. Cawkwell L, Bell SM, Lewis FA, et al. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 1993;67:1262-7.
26. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
27. Heideman DA, Snijders PJ, Bloemena E, et al. Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J Pathol 2001;194:428-35.
28. Saukkonen K, Nieminen O, van Rees B, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31.
29. Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999;6:290-7.
30. de Leng WWJ, Westerman AM, Weterman MAJ, et al. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 2003;9:3065-72.
31. van de Wetering M, Oosterwegel M, Holstege F, et al. The human T cell transcription factor-1 gene. Structure, localization, and promoter characterization. J Biol Chem 1992;267:8530-6.
32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
33. Jenkins GJ, Doak SH, Parry JM, et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002;89:824-37.
34. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001;233:322-37.
35. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
36. Menke-Pluymers MB, van Drunen E, Vissers KJ, et al. Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. Cancer Genet Cytogenet 1996;90:109-17.
37. El-Rifai W, Frierson HF Jr, Moskaluk CA, et al. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001;121:592-8.
38. Weiss MM, Kuipers EJ, Hermsen MA, et al. Barrett's adenocarcinomas resemble adenocarcinomas of the gastric cardia in terms of chromosomal copy number changes, but relate to squamous cell carcinomas of the distal oesophagus with respect to the presence of high-level amplifications. J Pathol 2003;199:157-65.
39. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000;119:854-65.
40. Choi YW, Heath EI, Heitmiller R, Forastiere AA, Wu TT. Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod Pathol 2000;13:1055-9.
41. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000;114:583-90.
42. Koppert LB, van der Velden AW, van de Wetering M, et al. Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear beta-catenin expression. Br J Cancer 2004;90:892-9.
43. Osterheld MC, Bian YS, Bosman FT, Benhattar J, Fontolliet C. Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol 2002;117:451-6.
44. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003;63:728-34.
45. van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.